Two previously described pedigrees with familial hyperproinsulinemia have elevated proinsulin conversion intermediates resulting from amino acid substitutions in the proinsulin molecule. In contrast, a third family with elevated levels of an apparently normal proinsulin molecule may have a defect in the converting process. To determine if the defect in this family lies in the insulin gene region, we used restriction fragment length polymorphisms adjacent to the insulin gene to examine cosegregation with hyperproinsulinemia. We demonstrate linkage of hyperproinsulinemia and the insulin gene in this family with a LOD score of 1.8, suggesting that the defect lies in or near the insulin gene. This method has wide applicability in determining whether hyperproinsulinemia or hyperinsulinemia is the result of defects at the insulin gene, and should permit the detection of new defects at or near this locus. DIABETES 1985; 34:821-24.
SUMMARY
Two previously described pedigrees with familial hyperproinsulinemia have elevated proinsulin conversion intermediates resulting from amino acid substitutions in the proinsulin molecule. In contrast, a third family with elevated levels of an apparently normal proinsulin molecule may have a defect in the converting process. To determine if the defect in this family lies in the insulin gene region, we used restriction fragment length polymorphisms adjacent to the insulin gene to examine cosegregation with hyperproinsulinemia. We demonstrate linkage of hyperproinsulinemia and the insulin gene in this family with a LOD score of 1.8, suggesting that the defect lies in or near the insulin gene. This method has wide applicability in determining whether hyperproinsulinemia or hyperinsulinemia is the result of defects at the insulin gene, and should permit the detection of new defects at or near this locus. DIABETES 1985; 34:821-24. W hile insulin gene mutations or structurally abnormal insulin molecules may play a substantial role in diabetes, few such pedigrees have been described. Of three families reported with diabetes and abnormal insulins, the defects in two are well characterized as Leu B25 insulin (Insulin Chicago) and Ser
B24
insulin. 12 Additionally, three families with hyperproinsulinemia have been described. 34 In two such families, elevated levels of des Arg 31 , Arg 32 proinsulin are present, a conversion intermediate in which the C-peptide remains attached to the A-chain. 3 In one of these families, the defect is known to result from the substitution of histidine for arginine at position 65.
5
The intermediates from these two families are indistinguishable by HPLC, 3 and thus the defects may be identical. The third hyperproinsulinemic family has high circulating levels of apparently normal proinsulin-like components (PLC), and appears to represent a different defect. 4 Like the other families, hyperproinsulinemia is inherited as an autosomal dominant disorder through three generations. Affected members had borderline glucose tolerance, but no overt diabetes. Because the PLC from this family converts to insulin with trypsin amounts appropriate to convert normal proinsulin to insulin, and because proinsulin intermediates seen in other familial hyperproinsulinemia were not present, the defect in this family was suggested to reside in the converting process rather than the proinsulin molecule. An insulin gene defect could be compatible with these results, however, if a subtle abnormality in the proinsulin molecule went undetected.
To test the hypothesis that the molecular defect in this family results from a mutation in or near the insulin gene, we investigated the segregation of hyperproinsulinemia with restriction fragment length polymorphisms (RFLPs) adjacent to the insulin gene. A highly polymorphic region of variable length 5' to the insulin gene (5' FP), 6 in addition to nearby site polymorphisms recently described (manuscript submitted), provides abundant polymorphism to perform such studies. We have demonstrated that linkage of the hyperproinsulinemia in this family to the insulin gene is highly probable. Therefore, the defect is likely to lie at or near the insulin locus.
METHODS
Hyperproinsulinemia. Hyperproinsulinemia was determined as previously described. 4 In addition to the family members described previously, individual II-2 was tested and found to be affected with a fasting insulin of 49.9 |xU/ml, proinsulinlike components of 68%, and a fasting plasma C-peptide of 0.74 pmol/ml. DNA extraction. DNA was obtained from 10 ml of heparinized blood, drawn from all individuals who were tested for LINKAGE ANALYSIS IN A HYPERPROINSULINEMIC FAMILY hyperproinsulinemia. Genomic DNA was prepared as previously described. Polymorphisms. All samples were digested with a fivefold excess of the restriction endonucleases Pvu II, Rsa I, and Taq I. Digests were run on 1.0% or 1.2% agarose gels and blotted to Zetabind (AMF Cuno). 8 All blots were hybridized with 32 P-probes, labeled by nick translation. 8 The region of length polymorphism 5' to the insulin gene was analyzed by hybridizing the Pvu II digest with a probe specific for the Pvu II fragment containing the polymorphic region. All samples were confirmed at least once.
Digests with Rsa I and Taq I were hybridized with a probe extending from -7.0 kilobase pairs (kb) to -13.0 kb, relative to transcription initiation, which demonstrates polymorphisms at Rsa I and Taq I sites at -1 3 and -1 1 kb, respectively. As recently described, Rsa I digests show hybridizing bands of 1.25 kb, denoted " + ," or 1.45 kb, denoted " -, " representing presence or absence of the Rsa I site. Likewise, Taq I digests show bands of 2.0 and 2.8 kb in the presence of the site ( + ) or 4.8 kb in the absence of the site ( -) . These polymorphisms have frequencies in Caucasians of + = 0.6 for Rsa I and + = 0.87 for Taq I (manuscript submitted). Since these sites are in linkage equilibrium with each other and with the 5' FP, they are very useful as genetic markers (manuscript submitted).
All Taq I digests were additionally hybridized with the probe pTBB2 (supplied by Ray White) for the region of length polymorphism 3' to the c-Ha-Ras oncogene. This polymorphism is located only 3 centimorgans from the insulin gene, 9 and although only confirmatory here, has been useful in many analyses. Linkage analysis. Maximum likelihood analysis of linkage between the RFLPs at the insulin locus and hyperproinsulinemia was performed using the computer algorithm PAP. 10 When multiple markers are tested for linkage, a logarithm base 10 of the odds ratio for the hypothesis of linkage versus nonlinkage, or LOD score, of greater than 3 is required. 11 However, when the linkage relationship between a specific genetic locus and a disease phenotype is tested, a much lower LOD score is acceptable.
RESULTS
The linkage relationship of familial hyperproinsulinemia and the insulin gene was determined by comparing segregation patterns of hyperproinsulinemia and insulin gene polymorphisms. Figure 1 
While the 5' FP is sufficient to establish linkage in this family, addition of recently described polymorphisms at Rsa I and Taq I sites ( -1 3 and -1 1 kb, respectively) permits the haplotypes contributed by each individual to be scored uniquely. The Rsa I and Taq I polymorphisms are designated " + " for presence of the site o r " -" for absence of the site (see METHODS). The combination of these three polymorphisms at the insulin locus permits haplotypes A-F to be distinguished (Figure 2 ). Allele A, contributed by individual 1-1, is shared by all hyperproinsulinemic individuals in three generations, but is not present in any unaffected individual. This inheritance is consistent both with the apparently autosomal The likelihood that this cosegregation of allele A with hyperproinsulinemia represents linkage rather than chance alone is formally quantified by calculating the logarithm of the odds ratio for linkage versus nonlinkage (random assortment), or LOD score, as shown in Table 1 . The calculated LOD score of 1.8 in this family represents 64:1 odds in favor of linkage, which is equivalent to a significance level of P = 0.015. While this value is much less than the LOD score of 3 (P < 0.001), which is said to prove linkage when multiple marker loci are tested, 11 this analysis nonetheless suggests linkage of hyperproinsulinemia and the insulin gene in this family with high probability.
DISCUSSION
Conventional studies of abnormal insulin and proinsulin molecules are necessarily compromised by the limited availability of protein for analysis. Recently, recombinant DNA technology has provided a powerful method for defining defects in insulin 1 and proinsulin 5 molecules. To date, however, such studies have analyzed DNA from individuals known to have amino acid substitutions for abnormal proinsulin intermediates. Without such evidence of an abnormal protein product to suggest a defective insulin gene, the physiologic significance of single base changes in the gene is uncertain. For example, allelic variation at several sites in noncoding regions of the insulin gene 12 seems to be of no functional significance. On the other hand, since the enzymes and precise mechanisms of posttranscriptional and posttranslational processing are largely unknown, insulin gene defects may exist that are unsuspected and perhaps undetectable by current methodology. Alternatively, perhaps defects in these processing enzymes could lead to the accumulation of proin- The present study suggests a rational approach to this dilemma, using DNA restriction fragment length polymorphisms (RFLPs) at the insulin locus to establish linkage of an abnormal insulin or proinsulin to the insulin gene. Because expected recombination between the polymorphic markers used here (5' FP, Rsa I, Taq I) and the structural insulin gene is essentially nonexistent, any failure of hyperproinsulinemia or an abnormal insulin to cosegregate with a given insulin allele eliminates the possibility of insulin gene mutations as an etiology of the defect. In such cases DNA sequencing of the insulin gene would not be fruitful. Interestingly, in a second pedigree with an apparently abnormal insulin, lack of linkage by this approach suggested that the defect did not reside at the insulin locus (unpublished observations). In the present pedigree, where linkage has been established, the potentially defective allele has been identified. Thus any changes present in the second allele would not explain the defect under investigation.
While lack of linkage between the insulin gene and diabetes has been established in several pedigrees with maturity-onset diabetes of youth (MODY), 13~15 this is the first study to demonstrate linkage of a defect to the insulin gene. This analysis incorporates several improvements over earlier studies. First, the region of length polymorphism (5' FP) was analyzed with Pvu II, which permits more alleles to be distinguished. Second, new polymorphisms at Rsa I and Taq I sites are included, thus permitting all alleles in this family to be identified. The additional polymorphism at the c-Ha-Ras locus, while unnecessary here, has low frequency of recombination with the insulin locus 9 and has been useful in other studies (unpublished observation). The use of these markers for linkage analysis has wide applicability in screening diabetic families for insulin gene defects, although the delayed onset and incomplete penetrance of diabetes in many families may limit this type of analysis. In contrast, since familial hyperproinsulinemia displays complete and early penetrance, no unaffected individual should inherit a defective allele.
Previous studies suggested that a defective converting enzyme may be responsible for the hyperproinsulinemia in this family. 4 In contrast, the present study provides substantial evidence for an insulin gene defect. Nonetheless, since linkage only implies physical proximity to our markers, this study is also compatible with a conversion defect in another gene were that gene located nearby. Consequently, if no defect is found in the insulin gene, this study could represent the first information on the location of those genes necessary for the conversion of proinsulin to insulin. initial suggestion to evaluate this family at the DNA level, Lynn Corsetti for assistance in DNA extraction and analysis, and Pam Rader and Pat Stewart for assistance in preparing this manuscript.
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